Skip to main content

Health policy or intellectual property policy? The fight over Bill C-91

Buy Article:

$54.08 plus tax (Refund Policy)

Abstract:

Adapted from the Canadian Healthcare Association's submission to the House of Commons Standing Committee on Industry currently reviewing Bill C-91, an Act to amend the Patent Act. Discusses the controversy surrounding this legislation, which extended patent protection to brand-name drug manufacturers to 20 years before generic copies of pharmaceuticals can be introduced on to the market.

Keywords: Canada; Patients; Pharmaceutical industry

Document Type: Research Article

DOI: http://dx.doi.org/10.1108/13660759710171691

Publication date: April 1, 1997

mcb/211/1997/00000010/00000002/art00002
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more